AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
AAPL   321.85 (+1.23%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
GE   6.76 (+2.89%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
Log in

NASDAQ:OSUROraSure Technologies Stock Price, Forecast & News

$14.12
-0.42 (-2.89 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.03
Now: $14.12
$14.48
50-Day Range
$10.82
MA: $14.80
$17.87
52-Week Range
$5.23
Now: $14.12
$18.27
Volume1.06 million shs
Average Volume948,995 shs
Market Capitalization$876.37 million
P/E Ratio70.60
Dividend YieldN/A
Beta0.51
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV-1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.
Read More
OraSure Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.09 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:OSUR
CUSIP68554V10
Phone610-882-1820

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$154.60 million
Cash Flow$0.24 per share
Book Value$4.98 per share

Profitability

Net Income$16.66 million

Miscellaneous

Employees398
Market Cap$876.37 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive OSUR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter.

OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions

How has OraSure Technologies' stock been impacted by COVID-19 (Coronavirus)?

OraSure Technologies' stock was trading at $5.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OSUR stock has increased by 139.3% and is now trading at $14.12. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of OraSure Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for OraSure Technologies.

When is OraSure Technologies' next earnings date?

OraSure Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for OraSure Technologies.

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) released its quarterly earnings results on Wednesday, May, 6th. The medical instruments supplier reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.06. The medical instruments supplier earned $31.60 million during the quarter, compared to the consensus estimate of $29.48 million. OraSure Technologies had a return on equity of 1.69% and a net margin of 8.06%. The company's revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.05) EPS. View OraSure Technologies' earnings history.

What price target have analysts set for OSUR?

2 equities research analysts have issued twelve-month target prices for OraSure Technologies' stock. Their forecasts range from $8.00 to $14.00. On average, they anticipate OraSure Technologies' stock price to reach $11.00 in the next twelve months. This suggests that the stock has a possible downside of 22.1%. View analysts' price targets for OraSure Technologies.

What are Wall Street analysts saying about OraSure Technologies stock?

Here are some recent quotes from research analysts about OraSure Technologies stock:
  • 1. According to Zacks Investment Research, "OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. " (5/6/2020)
  • 2. Canaccord Genuity analysts commented, "We stick with our HOLD rating and lower our PT from $9 to $7." (8/14/2019)

Has OraSure Technologies been receiving favorable news coverage?

Media stories about OSUR stock have been trending extremely positive recently, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OraSure Technologies earned a media sentiment score of 5.0 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutOraSure Technologies.

Who are some of OraSure Technologies' key competitors?

What other stocks do shareholders of OraSure Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), XOMA (XOMA), Energy Transfer LP Unit (ET), Overstock.com (OSTK), Ford Motor (F), CBL & Associates Properties (CBL), Alnylam Pharmaceuticals (ALNY), Celldex Therapeutics (CLDX) and Walt Disney (DIS).

Who are OraSure Technologies' key executives?

OraSure Technologies' management team includes the following people:
  • Dr. Stephen S. Tang, Pres, CEO & Director (Age 58)
  • Mr. Jack E. Jerrett, Sr. VP, Gen. Counsel & Sec. (Age 60)
  • Mr. Anthony Zezzo II, Exec. VP & Bus. Unit Leader of Infectious Disease (Age 65)
  • Mr. Brian L. Smith, Vice Chairman & EVP of Innovation - DNA Genotek, Inc. (Age 60)
  • Mr. Roberto E. Cuca, CFO & Principal Accounting Officer (Age 51)

What is OraSure Technologies' stock symbol?

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.12%), Wellington Management Group LLP (4.79%), State Street Corp (4.21%), Primecap Management Co. CA (2.63%), Systematic Financial Management LP (2.52%) and Geode Capital Management LLC (1.47%). Company insiders that own OraSure Technologies stock include Charles W Patrick, Jack E Jerrett, Roberto Cuca and Stephen S Phd Tang. View institutional ownership trends for OraSure Technologies.

Which major investors are selling OraSure Technologies stock?

OSUR stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, New York State Common Retirement Fund, Wellington Management Group LLP, Two Sigma Investments LP, BlackRock Inc., Nuveen Asset Management LLC, Russell Investments Group Ltd., and Assenagon Asset Management S.A.. View insider buying and selling activity for OraSure Technologies.

Which major investors are buying OraSure Technologies stock?

OSUR stock was purchased by a variety of institutional investors in the last quarter, including EAM Global Investors LLC, EAM Investors LLC, State Street Corp, Fred Alger Management LLC, Geode Capital Management LLC, Acadian Asset Management LLC, Wells Fargo & Company MN, and Aigen Investment Management LP. Company insiders that have bought OraSure Technologies stock in the last two years include Jack E Jerrett, Roberto Cuca, and Stephen S Phd Tang. View insider buying and selling activity for OraSure Technologies.

How do I buy shares of OraSure Technologies?

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OraSure Technologies' stock price today?

One share of OSUR stock can currently be purchased for approximately $14.12.

How big of a company is OraSure Technologies?

OraSure Technologies has a market capitalization of $876.37 million and generates $154.60 million in revenue each year. The medical instruments supplier earns $16.66 million in net income (profit) each year or $0.13 on an earnings per share basis. OraSure Technologies employs 398 workers across the globe.

What is OraSure Technologies' official website?

The official website for OraSure Technologies is www.orasure.com.

How can I contact OraSure Technologies?

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.